This is a working overview of peptide research, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-25. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
=== Effect of parental age and temperature === Offspring produced by older beetles have shorter larval stages than those produced by younger beetles. Larvae from the older beetles also show a rapid weight increase at an earlier age than those from young parents. At 25 °C, the larval stage was shortened, the number of larval molts decreased, and the durations of adult life decreased when parental age increased, compared to the beetles at 30 °C. Another study found that at 20°, 25°, and 30 °C, parental age does not have any effect on the duration of the egg stage, or the weights of the eggs. However, the amount of hatched eggs decreased when parental age increased. When eggs were laid during the first two months after emergence, approximately 90% of the eggs hatched. When they were laid after four months, only about 50% hatched. It was found that larvae from young parents grow at a slower rate, compared to larvae produced by the same parents, nine weeks earlier. At 30 °C, there were no other effects of parental age on the larvae. At 20° and 25 °C, the larvae from young parents required significantly more time to complete development, and had more molts compared to the larvae from the same parents after they had aged one more or longer. The duration of adult life decreased when parental age increased.
=== Microbiology === Over 40 phylogenetically and metabolically diverse microorganisms capable of growth using perchlorate as an electron acceptor have been isolated since 1996. Most originate from the Pseudomonadota, but others include the Bacillota, Moorella perchloratireducens and Sporomusa sp., and the archaeon Archaeoglobus fulgidus. With the exception of A. fulgidus, microbes that grow via perchlorate reduction utilize the enzymes perchlorate reductase and chlorite dismutase, which collectively take perchlorate to chloride. In the process, free oxygen (O2) is generated.
Benefits of decreased body mass index as well as HDL cholesterol were more strongly observed in studies with only a slight increase in protein intake rather where high protein intake was classified as 45% of total energy intake. Detrimental effects to cardiovascular activity were not observed in short-term diets of 6 months or less. There is little consensus on the potentially detrimental effects to healthy individuals of a long-term high protein diet, leading to caution advisories about using high protein intake as a form of weight loss. The 2015–2020 Dietary Guidelines for Americans (DGA) recommends that men and teenage boys increase their consumption of fruits, vegetables and other under-consumed foods, and that a means of accomplishing this would be to reduce overall intake of protein foods. The 2015–2020 DGA report does not set a recommended limit for the intake of red and processed meat. While the report acknowledges research showing that lower intake of red and processed meat is correlated with reduced risk of cardiovascular diseases in adults, it also notes the value of nutrients provided from these meats. The recommendation is not to limit intake of meats or protein, but rather to monitor and keep within daily limits the sodium (< 2300 mg), saturated fats (less than 10% of total calories per day), and added sugars (less than 10% of total calories per day) that may be increased as a result of consumption of certain meats and proteins.
The primary combat vehicles of the American divisions were the M1A1 Abrams tank and the Bradley Fighting Vehicle. The primary American artillery system was the self propelled M109 howitzer. The primary American attack helicopter was the Boeing AH-64 Apache (Army) with the Bell AH-1 Cobra (Army and Marines) also being in theatre. The U.S. Fairchild Republic A-10 Thunderbolt II ground attack aircraft would distinguish itself during the Gulf War aided by the OH-58D JAATT eyes in the sky. Together they inflicted significant damage on Iraqi ground forces. U.S. A-10 "Warthog" crews would destroy 900 Iraqi tanks, 2,000 other military vehicles and 1,200 artillery pieces during combat operations. The U.S. Marine Corps was represented by the 1st Marine Division and the 2nd Marine Division. They were supported by the U.S. Army's 2nd Armored Division's Tiger Brigade to provide the Marines with additional armor support. Marine armor units mostly consisted of the older M-60 tank. The 1st Marine Division destroyed around 60 Iraqi tanks near the Burgan oil field without suffering any losses. The 1st Marine Division Task Force Ripper led the drive to the Kuwait International Airport on 27 February 1991. Marine Task Force Ripper destroyed about 100 Iraqi tanks and armored personnel carriers, including T-72 tanks. The division commander Maj. Gen. J.M. Myatt said, "During the first day of combat operations 1st Platoon, D Company, 3rd Tank Battalion destroyed 15 Iraqi tanks". The Marines also destroyed 25 APCs and took 300 prisoners of war. The U.S.M.C.
Big dynorphin is an endogenous opioid peptide of the dynorphin family. It forms when a precursor protein prodynorphin is not fully processed, resulting in a 32-amino acid molecule containing both dynorphin A and dynorphin B sequences. It has the amino acid sequence: Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln-Lys-Arg-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr. Big dynorphin is a highly efficiacious principal endogenous agonist at the human κ-opioid receptor (KOR). It produces one of the strongest responses at GPR139 receptor among dynorphins. Additionally, it uniquely modulates NMDA receptor and potentiates acid-sensing ion channel 1a (ASIC1a). It plays a role in pain and stress responses. It exhibits both analgesic and pro-nociceptive properties. In mice it modulates memory and learning, and has anxiolytic properties, contributing to homeostatic regulation of opioid signaling in the central nervous system.
Sources: en.wikipedia.org
Governor William Robinson shared the same view with the former, insisted that a Medical Department with a Principal Civil Medical Officer directly under the Government should replace the Sanitary Board. With regard of the reconstitution of the Sanitary Board, Governor William Robinson conducted a plebiscite in June 1896. Besides the reconstitution of the Sanitary Board issues, in 1894 there was a group of petitioners supported by the Unofficial Members of the Legislative Council Paul Chater and Ho Kai with 363 signatures asked for a further representations in the Colonial Government. They demanded:
== History == Ketobemidone was first synthesized in 1942 by Eisleb and colleagues, at the laboratory of I.G. Farbenindustrie at Hoechst during the Second World War. The first study of it in humans was published in 1946, and it was introduced in clinical medicine shortly after. It was not in clinical use in the United States when the Controlled Substances Act 1970 was promulgated and was assigned to Schedule I with an ACSCN of 9628. As of 2013, no annual manufacturing quota was assigned by the DEA. Pfizer manufactures ketobemidone under the tradenames Ketogan and Ketorax. It is available as tablets, suppositories, and injection fluid. A sustained release formulation, sold as Ketodur, exists in some countries and contains 10 or 25 mg ketobemidone.
Prior to this, there had been failed synthesis attempts in 1986–87 at the Joint Institute for Nuclear Research in Dubna (then in the Soviet Union) and in 1990 at the GSI. A 1995 attempt at the Lawrence Berkeley National Laboratory resulted in signs suggesting but not pointing conclusively at the discovery of a new isotope 267Ds formed in the bombardment of 209Bi with 59Co, and a similarly inconclusive 1994 attempt at the JINR showed signs of 273Ds being produced from 244Pu and 34S. Each team proposed its own name for element 110: the American team proposed hahnium after Otto Hahn in an attempt to resolve the controversy of naming element 105 (which they had long been suggesting this name for), the Russian team proposed becquerelium after Henri Becquerel, and the German team proposed darmstadtium after Darmstadt, the location of their institute. The IUPAC/IUPAP Joint Working Party (JWP) recognised the GSI team as discoverers in their 2001 report, giving them the right to suggest a name for the element.
=== Cardiovascular === Adropin also appears to have cardiovascular effects. It has been implicated in the regulation of endothelial function, which is essential for maintaining blood vessel health. Dysfunction in endothelial cells can contribute to conditions such as atherosclerosis and hypertension. Some studies suggest that adropin may have a protective role in cardiovascular health by promoting the dilation of blood vessels and reducing oxidative stress. In mice, adropin regulates cardiac energy metabolism and improves cardiac function and efficiency. In rats, adropin treatment alleviated diabetes related myocardial fibrosis and diastolic dysfunction, and enhanced the therapeutic potential of mesenchymal stem cells in myocardial infarction.
==== Thalidomide ==== Despite the therapeutic potential of anti-angiogenesis drugs, they can also be harmful when used inappropriately. Thalidomide is one such antiangiogenic agent. Thalidomide was given to pregnant women to treat nausea. However, when pregnant women take an antiangiogenic agent, the developing fetus will not form blood vessels properly, thereby preventing the proper development of fetal limbs and circulatory systems. In the late 1950s and early 1960s, thousands of children were born with deformities, most notably phocomelia, as a consequence of thalidomide use.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.